V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Heron Therapeutics Executive Compensation (FY25)

HRTX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Craig Collard
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Heron Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 9, 2026Latest filing (8-K): June 16, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
The Pay Desk is the free weekly executive pay briefing — one company at a time, every number traceable to a public filing.
You’ll confirm on The Pay Desk’s sign-up page.
Heron Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
228 figures on this page: 217 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Craig Collard: $3,395,492 → $3,516,291 (3.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Heron Therapeutics' chief executive and what were they paid?
Craig Collard, Chief Executive Officer, received $3,516,291 in total compensation for fiscal 2025. Collard's total was 3.6% higher than the $3,395,492 reported for fiscal 2024.
What was Heron Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 86.5% of votes cast for or against in favor at the meeting held June 11, 2026.
Which companies are in Heron Therapeutics' peer group?
The disclosed peer group includes Akebia Therapeutics, ANI Pharmaceuticals, Coherus BioSciences, Collegium Pharmaceuticals and Esperion Therapeutics, among others.
What is Heron Therapeutics' chief executive pay ratio?
The company reported a chief executive pay ratio of 13.1:1 for fiscal 2025, against median employee compensation of $268,890.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kimberly Manhard
Executive Vice President, Drug Development
◇—◇◇◇—◇◇
David Szekeres
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Pharm.D. Barry Quart
Former Chief Executive Officer
Departed during or after this year
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Craig Collard
Chief Executive Officer
◇—◇◇◇—◇◇
Ira Duarte
EVP, Chief Financial Officer
◇—◇◇◇—◇◇
William Forbes
EVP, Chief Development Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Craig Collard
Chief Executive Officer
◇—◇◇◇——◇
William Forbes
EVP, Chief Development Officer
◇—◇◇◇——◇
Ira Duarte
EVP, Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Mark Hensley
EVP, Chief Operating Officer
◇—◇◇◇—◇◇
Craig Collard
Chief Executive Officer
◇—◇◇◇—◇◇
William Forbes
EVP, Chief Development Officer
◇—◇◇◇——◇
Ira Duarte
EVP, Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Craig CollardRSU◇——◇——◇
Craig CollardOPTION◇——◇—◇◇
Ira DuarteOPTION◇——◇—◇◇
Ira DuarteRSU◇——◇——◇
Mark HensleyRSU◇——◇——◇
Mark HensleyOPTION◇——◇—◇◇
Mark HensleyOPTION◇——◇—◇◇
William ForbesOPTION◇——◇—◇◇
William ForbesRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
William ForbesRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇6/6/2033
Option◇—◇1/19/2034
Option◇—◇1/31/2035
Ira DuarteOption◇—◇1/19/2034
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2035
Craig CollardRSU◇=——
RSU◇◇——
Option◇—◇4/3/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/19/2034
Option◇—◇1/31/2025
Mark HensleyRSU◇◇——
Option◇—◇4/28/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Tom Cusack
◇◇◇———◇
Adam Morgan
Board chair
◇◇◇———◇
Craig Johnson
◇◇◇———◇
Sharmila Dissanaike
◇◇◇———◇
Christian Waage
◇◇◇———◇
Michael Kaseta
◇◇◇———◇
Susan Rodriguez
◇◇◇———◇
Craig Collard served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Rsus/Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Akebia Therapeutics AKBA
  • ANI Pharmaceuticals ANIP
  • Coherus BioSciences CHRS
  • Collegium Pharmaceuticals COLL
  • Esperion Therapeutics ESPR
  • G1 Therapeutics GTHX
  • Harrow HROW
  • Innoviva INVA
  • Lexicon Pharmaceuticals LXRX
  • Ocular Therapeutics OCUL
  • OptiNose OPTN
  • Phantom Pharmaceuticals PHAT
  • Rigel Pharmaceuticals RIGL
  • Sage Therapeutics SAGE
  • Travere Therapeutics TVTX
  • UroGen Pharma URGN
  • Vanda Pharmaceuticals VNDA
  • Xeris Biopharma Holdings XERS
  • Y-mAbs Therapeutics YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2023June 13, 2024=◇◇◇
2022June 8, 2023=◇◇◇
2021May 24, 2022=◇◇◇
2020June 17, 2021=◇◇◇
2019June 17, 2020=◇◇◇
2018June 18, 2019=◇◇◇
2017June 18, 2018=◇◇◇
2016June 12, 2017=◇◇◇
2015June 21, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Craig Collard (Chief Executive Officer), FY2025 total compensation $3,516,291 (base salary $689,431) [exec_comp, SEC accession 0001193125-26-196306, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Heron Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Heron Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Heron Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Heron Therapeutics' disclosed peer group is defensible, who names Heron Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
228 figures on this page: 217 cited to the filing that reported them, 11 calculated from figures it prints.
217 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001193125-26-272388
    Proposal 3: The Company’s stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company’s Named Executive Officers during the fiscal year ended December 31, 2025: For Aga
  2. 0001193125-26-196306
    Grants of Plan-Based Awards
  3. 0000950170-24-074952
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-23-027374
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0000950170-23-016042
  6. 0001564590-22-021277
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001564590-21-033349
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-20-029788
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-19-176468
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-18-201200
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-17-202432
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-16-628925
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Heron Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/HRTX (accessed 2026).
Short form: data: Velarion

The Heron Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Heron Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Heron Therapeutics discloses

The companies named in HRTX's own disclosed peer group.

Akebia TherapeuticsANI PharmaceuticalsCoherus BioSciencesCollegium PharmaceuticalsEsperion TherapeuticsG1 TherapeuticsHarrowInnovivaLexicon PharmaceuticalsOcular TherapeuticsOptiNosePhantom PharmaceuticalsRigel PharmaceuticalsSage TherapeuticsTravere TherapeuticsUroGen PharmaVanda PharmaceuticalsXeris Biopharma HoldingsY-mAbs Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy